GSK says efficacy of its shingles vaccine remains high after years

FILE PHOTO: A box and vials of the drug Shingrix, made by GlaxoSmithKline Pharmaceutical, sit on a counter at a pharmacy in Provo

(Reuters) - British drugmaker GSK said on Wednesday long-term data showed that its blockbuster shingles vaccine, Shingrix, had 79.7% efficacy in participants aged 50 years and above, six to 11 years after vaccination.

The vaccine's efficacy remained high at 82% at year 11 after initial vaccination, GSK said, citing data from a long-term follow-up, late-stage trial that tracked participants for up to about 11 years after they were first vaccinated with Shingrix.

(Reporting by Yadarisa Shabong in Bengaluru; Editing by Savio D'Souza)